Philip Morris International Inc

Business description

Philip Morris International is the world's largest publicly traded tobacco company, with a 29.2% share of international cigarette and heated tobacco volumes (excluding China). PM sells 607B cigarettes annually under marquee brands like Marlboro, Parliament, and Virginia Slims, while rapidly pivoting to smoke-free products — ZYN nicotine pouches and IQOS heated tobacco — which now constitute 42% of revenue and 43% of gross profit (2025).

Key financials

• Price: USD 192.98 (07/17/2026)
• 12-Mo Target: USD 175.00
• Market Cap: USD 300.77B
• CFRA Rating: Hold
• H-Score: 75

Competitive moat

• Dominant global tobacco market share (29.2% ex-China) with iconic premium brands (Marlboro) providing exceptional pricing power and 67% gross margins among the highest in Consumer Staples.
• First-mover advantage in heated tobacco (IQOS) and nicotine pouches (ZYN), with smoke-free products growing 12.8% in volume and now 42% of revenue.
• High barriers to entry from heavy regulation, excise taxation, and litigation risk protect incumbent positions.
• Stellar earnings track record — only one quarterly miss (Q4 2023) since 2017, reflecting conservative guidance and consistent execution.
• Defensive characteristics: low beta (0.4), 3%+ dividend yield with 18 consecutive years of dividend increases, and ample free cash flow.

Recent developments

• Smoke-free momentum: Smoke-free products reached 42% of revenue in 2025; ZYN nicotine pouches and IQOS driving top-line growth, offsetting cigarette volume declines of 2.2%.
• Q1 2026 beat: Adjusted EPS of $1.96 (+16% Y/Y) ahead of consensus; revenues up 9.1% driven by pricing and smoke-free volume (+9.1%).
• Swedish Match acquisition integration: $14B deal closed in 2022 continues to drive oral product growth; ZYN Ultra launched in U.S. seen as catalyst.
• Currency tailwind: Weakening U.S. dollar providing a $0.25/share EPS benefit in 2026, up from $0.04 in 2025.

Investment risks / red flags

• CFRA is Hold with $175 target: Stock at $192.98 trades above CFRA's $175 target; risk/reward seen as balanced after significant outperformance.
• Regulatory pressure: Italy penalty for misleading "smoke-free" marketing; ongoing global regulatory scrutiny on nicotine products; potential flavor bans and marketing restrictions.
• Secular volume decline: Global cigarette consumption declining ~2% annually; developed markets declining mid-single-digit; any shift in consumer habits away from nicotine would compound headwinds.
• Currency exposure: Despite near-term tailwinds, significant non-U.S. operations create ongoing FX translation risk.
• Elevated debt: Total debt of $51.9B (116% debt/capital) following Swedish Match acquisition; share repurchase program remains suspended.

H-Score signals

• TBI multi factor score: 75
• Moderate score reflecting defensive value and momentum, balanced against secular volume decline and valuation risk.

Theme exposure

• [[consumer-staples]]
• [[smoke-free-products]]

Related

• [[Consumer Staples]]
• [[Altria Group Inc]]